Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer

Fig. 4

Correlation between the clinical response to atezolizumab in the IMVigor 210 study according to RECIST v1.1 criteria and a the Tumor Mutational Burden (TMB) and b the TMM. CR: Complete Response; PR: Partial Response; SD: Stable Disease; PD: Progressive disease. ** P value < 0.01; *** P value < 0.001, Wilcoxon rank sum test, two-sided

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us